CA3246157A1 - TYK2 INHIBITORS AND THEIR USES - Google Patents
TYK2 INHIBITORS AND THEIR USESInfo
- Publication number
- CA3246157A1 CA3246157A1 CA3246157A CA3246157A CA3246157A1 CA 3246157 A1 CA3246157 A1 CA 3246157A1 CA 3246157 A CA3246157 A CA 3246157A CA 3246157 A CA3246157 A CA 3246157A CA 3246157 A1 CA3246157 A1 CA 3246157A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- patient
- psoriasis
- hours
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263269943P | 2022-03-25 | 2022-03-25 | |
| US63/269,943 | 2022-03-25 | ||
| US202263371033P | 2022-08-10 | 2022-08-10 | |
| US63/371,033 | 2022-08-10 | ||
| US202363490664P | 2023-03-16 | 2023-03-16 | |
| US63/490,664 | 2023-03-16 | ||
| PCT/US2023/064902 WO2023183901A1 (en) | 2022-03-25 | 2023-03-24 | Tyk2 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3246157A1 true CA3246157A1 (en) | 2023-09-28 |
Family
ID=88102041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3246157A Pending CA3246157A1 (en) | 2022-03-25 | 2023-03-24 | TYK2 INHIBITORS AND THEIR USES |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250213572A1 (enExample) |
| EP (1) | EP4499104A4 (enExample) |
| JP (1) | JP2025510813A (enExample) |
| KR (1) | KR20240165963A (enExample) |
| AU (1) | AU2023237900A1 (enExample) |
| CA (1) | CA3246157A1 (enExample) |
| CL (1) | CL2024002824A1 (enExample) |
| MX (1) | MX2024011693A (enExample) |
| TW (1) | TW202345799A (enExample) |
| WO (1) | WO2023183901A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024263861A2 (en) * | 2023-06-23 | 2024-12-26 | Dana-Farber Cancer Institute, Inc. | Methods of treating chronic lymphocytic leukemia |
| EP4780462A1 (en) * | 2023-09-21 | 2026-07-29 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
| CN122341608A (zh) * | 2023-11-24 | 2026-07-03 | 苏州科睿思制药有限公司 | Zasocitinib的晶型及其制备方法和用途 |
| WO2026032374A1 (zh) * | 2024-08-07 | 2026-02-12 | 正大天晴药业集团股份有限公司 | 含联环的化合物用于治疗银屑病的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL317854A (en) * | 2017-07-28 | 2025-02-01 | Takeda Pharmaceuticals Co | TYK2 inhibitors and their uses |
| JP7619951B2 (ja) * | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| US11357775B2 (en) * | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
-
2023
- 2023-03-24 KR KR1020247032947A patent/KR20240165963A/ko active Pending
- 2023-03-24 WO PCT/US2023/064902 patent/WO2023183901A1/en not_active Ceased
- 2023-03-24 US US18/850,466 patent/US20250213572A1/en active Pending
- 2023-03-24 JP JP2024556626A patent/JP2025510813A/ja active Pending
- 2023-03-24 CA CA3246157A patent/CA3246157A1/en active Pending
- 2023-03-24 EP EP23775910.5A patent/EP4499104A4/en active Pending
- 2023-03-24 AU AU2023237900A patent/AU2023237900A1/en active Pending
- 2023-03-25 TW TW112111352A patent/TW202345799A/zh unknown
-
2024
- 2024-09-23 CL CL2024002824A patent/CL2024002824A1/es unknown
- 2024-09-24 MX MX2024011693A patent/MX2024011693A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024011693A (es) | 2024-11-08 |
| US20250213572A1 (en) | 2025-07-03 |
| EP4499104A1 (en) | 2025-02-05 |
| AU2023237900A1 (en) | 2024-10-10 |
| JP2025510813A (ja) | 2025-04-15 |
| EP4499104A4 (en) | 2025-09-03 |
| KR20240165963A (ko) | 2024-11-25 |
| TW202345799A (zh) | 2023-12-01 |
| CL2024002824A1 (es) | 2025-02-14 |
| WO2023183901A1 (en) | 2023-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250213572A1 (en) | Tyk2 inhibitors and uses thereof | |
| US12338242B2 (en) | TYK2 inhibitors and uses thereof | |
| US20260049095A1 (en) | Deuterated stat3 degraders and uses thereof | |
| TWI783978B (zh) | Tyk2抑制劑、其用途及生產方法 | |
| US20230322754A1 (en) | Irak inhibitors and uses thereof | |
| JP2025534698A (ja) | Ｉｒａｋ４デグレーダーの塩の形態 | |
| WO2024064080A1 (en) | Stat6 degraders and uses thereof | |
| JP2024506858A (ja) | Ｇｐｒ８４アンタゴニストおよびその使用 | |
| US20240262830A1 (en) | Ire1a modulators and uses thereof | |
| WO2024028365A1 (en) | Substituted pyridone gpr84 antagonists and uses thereof | |
| US20250215002A1 (en) | Solid forms of tyk2 inhibitors and methods of use | |
| AU2023317741A1 (en) | Aryl-triazolyl and related gpr84 antagonists and uses thereof | |
| US20250206743A1 (en) | Tyk2 inhibitor synthesis and intermediates thereof | |
| EP4452940A1 (en) | Oxer1 antagonists and uses thereof | |
| AU2023317740A1 (en) | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof | |
| JP2025510859A (ja) | Ｔｙｋ２阻害剤製剤及びその作製方法 | |
| CN118973583A (zh) | Tyk2抑制剂及其用途 | |
| WO2025062372A1 (en) | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240917 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240920 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240920 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240920 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250213 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250226 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250226 |